Search results
18 lip 2023 · Patient-related prognostic factors include age and comorbidities. According to the Revised International Prognostic Scoring System (IPSS-R), age at diagnosis discernibly influences the prognosis of patients with low-risk MDS but has only a limited effect on those with high-risk MDS.
Survival statistics for MDS. The following survival statistics are divided by the Molecular International Prognostic Scoring System (IPSS-M) risk groups. Again, it’s important to note that this system is based largely on people who were diagnosed with MDS and treated many years ago.
Life expectancy with MDS can range depending on what type of MDS you have, how likely it is that the MDS will become leukemia, and other risk factors. Your doctor may use a scoring system to...
Your individual prognosis will be affected by many things, including: your age; your general fitness and health; the type of MDS you have; the MDS risk group you are in. Finding out about your prognosis can be scary, especially if you’ve been told you are in a higher risk group.
Patients in the very high risk group have a median survival time of only 0.8 years, whereas median survival for patients in the very low risk group is 8.8 years, hardly different from the life expectancy of the age-matched healthy population .
27 maj 2012 · The overall 3-year survival rate was 32%; lower for females than for males. Overall survival of patients with bone marrow blasts less than 10% is better than those which presented higher than 10% bone marrow blasts, with significant difference.
6 kwi 2023 · Over two decades, age-standardised 5-year RS increased from 37 to 62%. Age-specific survival improved from 41% in period 2000–2004 to 69% in period 2015–2019 in the age group 15–69 years, and from 23 to 47% in the age group 70–79 years.
